Cargando...

Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis

BACKGROUND: Infliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis. METHODS: An...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sweiss, Nadera J., Noth, Imre, Mirsaeidi, Mehdi, Zhang, Wei, Naureckas, Edward T., Hogarth, D. Kyle, Strek, Mary, Caligiuri, Philip, Machado, Roberto F, Niewold, Timothy B, Garcia, Joe G.N., Pangan, Aileen L., Baughman, Robert P.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4134103/
https://ncbi.nlm.nih.gov/pubmed/24751453
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!